Health Canada Allows Phase IIa Clinical Trial in COVID-19 Patients with Respiratory Failure

NuvOx Pharma
Jun 29, 2020
1 min read

NuvOx Pharma has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).

See Press Release

Recent Posts

See All

NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction

NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction Tucson, AZ – March 4, 2025 - NuvOx...

NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial

Tucson, AZ – January 21,2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency...

NuvOx Announces Two New Publications

NuvOx Announces Two New Publications Tucson, AZ – October 21, 2024 - Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine...

Comments